Shares of Catalyst Pharma rose more than 3% in the pre-market session after the commercial-stage biopharmaceutical company announced its stock repurchase program of …
Catalyst Pharmaceuticals delivered a better-than-expected 4Q performance, driven by higher sales for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS) patients. …
With the market’s trajectory remaining unknown, hedge fund manager Steven Boyd believes that one industry in particular still houses exciting opportunities: the healthcare …
Investors are constantly searching for the next big winner. We mean the stocks that are on track to see explosive growth, handsomely rewarding …
This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted over 50%. So what …
This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted nearly 55%. What’s causing …
Catalyst Pharmaceuticals (CPRX) hosted a conference call yesterday to discuss its commercialization plan for the company’s newly FDA-approved LEMS drug, Firdapse. Catalyst announced …
Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …
H.C.
Every small-cap biotechnology investor knows the industry is prone to binary events. Whether it’s receiving updates from an important clinical trial or hearing …